Investment Highlights

With new and unique technologies and active substances, the biopharmaceutical company MOLOGEN is one of the pioneers in the field of immunotherapy. Alongside a focus on immuno-oncology, MOLOGEN also develops immunotherapies for the treatment of infectious diseases.

What sets us apart:

  • Biopharmaceutical company developing ground-breaking immunotherapies
  • Lead product lefitolimod (MGN1703): potential blockbuster candidate
  • Targeting indications with high unmet medical needs: Cancer and HIV
  • Attractive for partnering/licensing: Advanced, close-to-market product candidate with long-term exclusivity and promising next generation successor molecules

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Biopharmaceutical Company MOLOGEN AG today announced that the reverse share split in a ratio of 5:1 resolved at the Company’s Annual... [more]

Annual Report 2017

Download pdf

Quarterly Statement as at 31 March 2018

Download pdf

June 8, 2018

Annual General Meeting

April 25, 2018

Annual Report 2017

 

Show complete Corporate Calendar.

25 September 2018

Berenberg & Goldman Sachs 7th German Corporate Conference, Munich, Germany

 

13 September 2018

Dr Kalliwoda Capital Markets Conference, Amsterdam, Netherlands

 

03 - 04 September 2018

Equity Forum Autumn Conference, Frankfurt, Germany


Show complete calendar.

 

 

 

 

Share Price

Contact:

Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Phone: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com

Distribution list

If you would like to receive our press releases, please click here.